# Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic Colorectal Cancer.

> **NCT03688230** · PHASE2 · WITHDRAWN · sponsor: **SFJ Pharmaceuticals X, LTD.**

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** abituzumab
- **COMBINATION_PRODUCT:** Placebo + Cetuximab + FOLFIRI

## Key facts

- **NCT ID:** NCT03688230
- **Lead sponsor:** SFJ Pharmaceuticals X, LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-04
- **Primary completion:** 2020-12
- **Final completion:** 2021-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Co-development decision
- **Last updated:** 2020-03-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03688230

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03688230, "Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic Colorectal Cancer.". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03688230. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*